×
About 173 results

ALLMedicine™ Hyperviscosity Syndrome Center

Research & Reviews  64 results

Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128329
Clinical and Experimental Medicine; Al-Kuraishy HM, Al-Gareeb AI et. al.

May 25th, 2022 - Hyperviscosity syndrome (HVS) recently emerged as a complication of coronavirus disease 2019 (COVID-19) and COVID-19 vaccines. Therefore, the objectives of this critical review are to establish the association between COVID-19 and COVID-19 vaccine...

T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966494
BMJ Case Reports; Avelino AR, Elmanaseer O et. al.

Mar 31st, 2022 - We describe the case of a man in his 60s with squamous cell carcinoma of the lung with brain metastasis treated with pembrolizumab who subsequently developed T-cell prolymphocytic leukaemia. He was transferred to our hospital with worsening dyspno...

The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advance...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960698
Clinical and Experimental Medicine; Dammacco F, Lauletta G et. al.

Mar 30th, 2022 - Immunoglobulins that reversibly precipitate at temperatures below 37 °C are called cryoglobulins (CGs). Cryoglobulinemia often manifests as cryoglobulinemic vasculitis (CV), whose symptoms range in severity from purpuric eruptions to life-threaten...

Plasma-free Replacement in Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05251896

Feb 23rd, 2022 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...

Waldenstrom Macroglobulinemia
http://emedicine.medscape.com/article/207097-overview

Feb 3rd, 2022 - Practice Essentials Waldenström macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. [1, 2] It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M ...

see more →

Clinicaltrials.gov  2 results

Plasma-free Replacement in Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05251896

Feb 23rd, 2022 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT04898647

May 24th, 2021 - Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hyperviscosity syndrome (HVS) are related to the large ...

see more →

News  3 results

MGUS, SPEP, and the Shaka Sign
https://www.medscape.com/viewarticle/944772

Feb 5th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: I am Dr Frank Watto, and that is Dr Stuart K. Brigham. With us is our good friend, Dr Paul Nelson Williams. Paul N. Williams, MD: This time around we are going to talk about our ep...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Feb 1st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Mayo experts outline Waldenström macroglobulinemia management
https://www.mdedge.com/hematologynews/nhlhub/article/152579/indolent-lymphoma/mayo-experts-outline-waldenstrom
Mary Ellen Schneider

Nov 21st, 2017 - Four to six cycles of bendamustine/rituximab is the primary regimen of choice for symptomatic, treatment-naive patients with Waldenström macroglobulinemia, especially when rapid control is needed for bulky disease, according to treatment guideline.

see more →